Johnson & Johnson on Wednesday proposed a plan to pay nearly $6.5 billion to resolve tens of thousands of lawsuits claiming that its cosmetic talc-based powder causes cancer. Through a ...
May 1 (UPI) --Pharmaceutical giant Johnson & Johnson on Wednesday said it is taking steps to resolve a multibillion dollar, cancer-related lawsuit with thousands of individuals over claims that ...
A subsidiary of Johnson & Johnson (J&J) is proposing to pay nearly $6.5 billion to resolve nearly all the talc ovarian cancer lawsuits brought against the company. J&J said the subsidiary plans to ...
Johnson and Johnson reiterated in its statement on Wednesday, May 1, that “none of the talc-related claims against it have merit” Charna Flam is a writer-reporter at PEOPLE. She has been ...
Johnson & Johnson has allocated a reserve totaling $11 billion to accommodate talc-related settlements. The proposed settlement aims to address the majority of talc-related litigation regarding ...
Johnson and Johnson is set to make one of the biggest payouts in history over claims its talc powder causes ovarian cancer. Under the proposed deal, the pharma giant would pay nearly $6.5billion ...
TAR-210 is an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder. TAR-210 is an intravesical targeted releasing system designed ...
Johnson & Johnson said Wednesday it has offered to pay $6.5 billion to settle allegations that its talc products caused cancer, a key step in the pharmaceutical giant potentially resolving decades ...
Johnson & Johnson Will Pay $6.5 Billion to Settle Talc Ovarian Cancer Lawsuits By Ernie Mundell HealthDay Reporter THURSDAY, May 2, 2024 (HealthDay News) -- Johnson & Johnson announced Wednesday ...
Benzinga - by Vandana Singh, Benzinga Editor. Wednesday, Johnson & Johnson (NYSE:JNJ) announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsuits related to ...
Benzinga - by Vandana Singh, Benzinga Editor. On Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter, multi-cohort Phase 1 study of TAR-210 in patients with ...
The deal is pending, requiring the approval of 75% of claimants THURSDAY, May 2, 2024 (HealthDay News) -- Johnson & Johnson announced Wednesday that it would pay out more than $6.5 billion over ...